DVA vs PPCB · P/E 14, rev $12.82B vs P/E 0.0, $3.9M cap
DaVita HealthCare Partners Inc (DVA) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
DaVita HealthCare Partners Inc (DVA) is a medical care facilities company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported DVA revenue for 2024-12-31 was $12.82B. Net income was $1.25B. Revenue was up 5.6% from 2023-12-31 to 2024-12-31. DVA currently screens at market cap $10.77B and trailing P/E 14.1.
PPCB does not have a complete income-statement cache yet.
DVA currently screens at market cap $10.77B and trailing P/E 14.1. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the DVA and PPCB stock pages for the full models.
Not investment advice.